Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger

OnKure Therapeutics, Inc.

Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.
Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.
Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.
Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.